keyword
MENU ▼
Read by QxMD icon Read
search

ovarian cancer cytoreduction

keyword
https://www.readbyqxmd.com/read/28631775/-innovations-in-the-treatment-of-ovarian-cancer-analysis-of-the-therapeutic-development-from-platinum-to-immunotherapy
#1
Gesuino Angius, Pierangela Sepe, Anselmo Papa, Silverio Tomao, Federica Tomao
Ovarian cancer is the seventh most common cancer in women. The therapeutic approach provides for an appropriate integration between surgery and chemotherapy. Surgery is an important step for diagnosis, staging and therapy, aiming at the complete cytoreduction of all macroscopic visible disease. At the moment, adjuvant and first-line chemotherapy has as a standard the carboplatin-paclitaxel combination. Further, the addition of bevacizumab in the advanced stage (IIIB-IV) is strongly recommended. Despite the initial effectiveness, however, 70-80% of patients develop relapsed disease within the first two years and require subsequent treatment lines that have palliative, rather than curative purposes and that seek to reach a chronic state for the disease...
June 2017: Recenti Progressi in Medicina
https://www.readbyqxmd.com/read/28631233/interval-robotic-cytoreduction-following-neoadjuvant-chemotherapy-in-advanced-ovarian-cancer
#2
Sarah A Ackroyd, Sajeena Thomas, Cynthia Angel, Richard Moore, Philip J Meacham, Brent DuBeshter
The objective of this study is to review our experience with robotic interval cytoreduction following neoadjuvant chemotherapy for advanced ovarian cancer. We retrospectively reviewed patients with advanced ovarian cancer treated with neoadjuvant chemotherapy (NAC) and interval robotic cytoreduction (IRC) between 2011 and 2016 at the University of Rochester Medical Center. Demographic information, chemotherapy treatment, operative results, and follow-up were extracted from medical records. Twenty-nine patients underwent IRC after a mean of 3...
June 19, 2017: Journal of Robotic Surgery
https://www.readbyqxmd.com/read/28628712/hyperthermic-intraperitoneal-chemoperfusion-as-a-component-of-multimodality-therapy-for-ovarian-and-primary-peritoneal-cancer
#3
Deepa Magge, Lekshmi Ramalingam, Yongli Shuai, Robert P Edwards, James F Pingpank, Steven S Ahrendt, Matthew P Holtzman, Herbert J Zeh, David L Bartlett, Haroon A Choudry
BACKGROUND AND OBJECTIVES: The role of hyperthermic intraperitoneal chemoperfusion (HIPEC) in the multimodality treatment of ovarian peritoneal metastases (OPM) and primary peritoneal cancer (PPC) remains controversial. We hypothesized that cytoreductive surgery (CRS) and HIPEC would provide meaningful survival benefit without excessive morbidity. METHODS: We reviewed clinicopathologic and perioperative data following 96 CRS-HIPEC procedures for primary or recurrent OPM and PPC...
June 19, 2017: Journal of Surgical Oncology
https://www.readbyqxmd.com/read/28628421/high-grade-serous-ovarian-cancer-associations-between-brca-mutation-status-ct-imaging-phenotypes-and-clinical-outcomes
#4
Stephanie Nougaret, Yulia Lakhman, Mithat Gönen, Debra A Goldman, Maura Miccò, Melvin D'Anastasi, Sarah A Johnson, Krishna Juluru, Angela G Arnold, Ramon E Sosa, Robert A Soslow, Hebert Alberto Vargas, Hedvig Hricak, Noah D Kauff, Evis Sala
Purpose To investigate the associations between BRCA mutation status and computed tomography (CT) phenotypes of high-grade serous ovarian cancer (HGSOC) and to evaluate CT indicators of cytoreductive outcome and survival in patients with BRCA-mutant HGSOC and those with BRCA wild-type HGSOC. Materials and Methods This HIPAA-compliant, institutional review board-approved retrospective study included 108 patients (33 with BRCA mutant and 75 with BRCA wild-type HGSOC) who underwent CT before primary debulking...
June 16, 2017: Radiology
https://www.readbyqxmd.com/read/28628188/silencing-of-bag3-promotes-the-sensitivity-of-ovarian-cancer-cells-to-cisplatin-via-inhibition-of-autophagy
#5
Shuang Qiu, Liang Sun, Ye Jin, Qi An, Changjiang Weng, Jianhua Zheng
Ovarian cancer is the most lethal disease among all gynecological malignancies. Interval cytoreductive surgery and cisplatin‑based chemotherapy are the recommended therapeutic strategies. However, acquired resistance to cisplatin remains a big challenge for the overall survival and prognosis in ovarian cancer. Complicated molecular mechanisms are involved in the process. At present, increasing evidence indicates that autophagy plays an important role in the prosurvival and resistance against chemotherapy...
July 2017: Oncology Reports
https://www.readbyqxmd.com/read/28626402/effect-of-the-combination-of-trabectedin-and-pegylated-liposomal-doxorubicin-in-a-brca2-mutation-carrier-with-recurrent-platinum-sensitive-ovarian-cancer
#6
María Jesús Rubio Pérez
INTRODUCTION: The current standard of care for ovarian cancer is optimal cytoreduction with adjuvant chemotherapy based on a platinum/taxane combination. Although the response rate to this therapy is high, most patients ultimately relapse. Response to second-line therapy and prognosis are linked to the platinum-free interval (PFI); when both improve, the PFI increases. As a result, there is an increasing interest in the PFI extension strategies including platinum-free combinations. CASE PRESENTATION: A 50-year-old postmenopausal woman presented with ovarian serous carcinoma with peritoneal carcinomatosis...
May 2017: Case Reports in Oncology
https://www.readbyqxmd.com/read/28624153/impact-of-ascites-volume-on-clinical-outcomes-in-ovarian-cancer-a-cohort-study
#7
J Brian Szender, Tiffany Emmons, Sarah Belliotti, Danielle Dickson, Aalia Khan, Kayla Morrell, A N M Nazmul Khan, Kelly L Singel, Paul C Mayor, Kirsten B Moysich, Kunle Odunsi, Brahm H Segal, Kevin H Eng
OBJECTIVES: To investigate the impact of ascites volume on ovarian cancer outcomes. METHODS: Clinicopathologic features of a cohort of patients with ovarian cancer were obtained from a curated database at a single institution. Progression free survival (PFS) and overall survival (OS) were recorded. Ascites volume at primary surgery was dichotomized at 2000mL and comparisons for high and low volume ascites were made. Additionally, to elucidate interactions between ascites and ovarian tumor progression, we evaluated the effect of intraperitoneal administrations of murine cell-free ascites versus saline in a syngeneic mouse model of epithelial ovarian cancer...
June 14, 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/28614136/surgery-for-patients-with-newly-diagnosed-advanced-ovarian-cancer-which-patient-when-and-extent
#8
Florine A Eggink, Corine M Koopmans, Hans W Nijman
PURPOSE OF REVIEW: Cytoreduction to no residual disease is the mainstay of primary treatment for advanced epithelial ovarian cancer (AdvEOC). This review addresses recent insights on optimal patient selection, timing, and extent of surgery, intended to optimize cytoreduction in patients with AdvEOC. RECENT FINDINGS: Clinical guidelines recommend primary cytoreductive surgery (PCS) for AdvEOC patients with a high likelihood of achieving complete cytoreduction with acceptable morbidity...
June 13, 2017: Current Opinion in Oncology
https://www.readbyqxmd.com/read/28610414/role-of-galectin-3-combined-with-multi-detector-contrast-enhanced-computed-tomography-in-predicting-disease-recurrence-in-patients-with-ovarian-cancer
#9
Emanuela Anastasi, Silvia Gigli, Maria Santulli, Sara Tartaglione, Laura Ballesio, Maria Grazia Porpora, Teresa Granato, Carlo Catalano, Antonio Angeloni, Lucia Manganaro
Galectin-3 (Gal-3) is an endogenous β-galactoside-binding lectin, playing an important role in the pathogenesis of multiple malignancies. Aim of the study was to evaluate in a group of patients treated for ovarian cancer (EOC), the role of Gal-3 combined with multi-detector contrast-enhanced computed tomography (MDCT), as predictor of recurrence disease. Seventeen follow-up patients with recurrent ovarian cancer and 13 follow-up patients with stable ovarian disease, who performed MDCT at one-year follow-up after cytoreductive treatment, were enrolled...
May 1, 2017: Asian Pacific Journal of Cancer Prevention: APJCP
https://www.readbyqxmd.com/read/28599137/management-of-advanced-ovarian-cancer-in-south-west-wales-a-comparison-between-primary-debulking-surgery-and-primary-chemotherapy-treatment-strategies-in-an-unselected-consecutive-patient-cohort
#10
F Drews, G Bertelli, K Lutchman-Singh
OBJECTIVES: This study represents the first reported outcomes for patients with advanced ovarian cancer (AOC) in South-West Wales undergoing treatment with primary debulking surgery or primary chemotherapy respectively. METHODS: This is a retrospective study of consecutive, unselected patients with advanced ovarian, fallopian tube or primary peritoneal cancer (FIGO III/IV) presenting to a regional cancer centre between October 2007 and October 2014. Patients were identified from Welsh Cancer Services records and relevant data was extracted from electronic National Health Service (NHS) databases...
June 6, 2017: Cancer Epidemiology
https://www.readbyqxmd.com/read/28585317/modified-posterior-pelvic-exenteration-for-advanced-ovarian-malignancies-a-single-institution-study-of-35-cases
#11
Lubos Minar, Michal Felsinger, Ivo Rovny, Filip Zlamal, Julie Bienertova-Vasku, Eva Jandakova
INTRODUCTION: This study aimed to investigate the possible benefits of a complete cytoreduction in patients with advanced ovarian cancer and concomitant rectal invasion. Furthermore, we evaluated the morbidity associated with radical surgery. MATERIAL AND METHODS: A retrospective analysis examined 35 cases that underwent radical surgery in the form of modified posterior pelvic exenteration (MPPE). Descriptive statistics, Kaplan-Meier survival curves and Log-Rank test were used for statistical estimations...
June 6, 2017: Acta Obstetricia et Gynecologica Scandinavica
https://www.readbyqxmd.com/read/28580507/retrospective-evaluation-of-thromboembolism-risk-in-ovarian-cancer-patients-treated-with-bevacizumab
#12
Anna Kuk, Magdalena Magnowska, Wiktor Suchy, Joanna Swierczynska, Mikolaj Piotr Zaborowski, Michal Gaca, Ewa Nowak-Markwitz
BACKGROUND: Bevacizumab is used in addition to standard, platinum-based chemotherapy to treat advanced-stage ovarian cancer patients. Thrombosis is a well-documented adverse effect of bevacizumab. OBJECTIVE: The aim of this study was to identify predictive parameters for thromboembolic events in ovarian cancer patients and to explain how bevacizumab increases the risk of these events. PATIENTS AND METHODS: Fifty-seven FIGO stage III ovarian cancer patients who underwent cytoreductive surgery and chemotherapy were identified and included in this retrospective study...
June 4, 2017: Targeted Oncology
https://www.readbyqxmd.com/read/28551658/preoperative-ca-125-values-as-a-predictive-factor-for-the-postoperative-outcome-in-primary-serous-ovarian-cancer
#13
Mustafa Zelal Muallem, Asya Parashkevova, Jumana Almuheimid, Rolf Richter, Yasser Diab, Elena Ioana Braicu, Jalid Sehouli
BACKGROUND/AIM: The purpose of the study was to examine the preoperative CA-125 values as a predictive factor for postoperative outcome in primary serous ovarian cancer (POC) for complete tumor resection (CTR) and evaluate the preoperative CA-125 levels with other vital clinical dynamics such as ascites, lymph node involvement, diffuse peritoneal carcinomatosis, grading and staging. PATIENTS AND METHODS: A cohort of 277 POC-patients aged 18-75 years, who had undergone primary cytoreductive surgery at the Department of Gynecology & Oncological Surgery, Charité, Campus Virchow Klinikum (CVK) between 2000 und 2009 was analyzed in correlation with the preoperative CA-125 values...
June 2017: Anticancer Research
https://www.readbyqxmd.com/read/28541636/survival-outcomes-after-extensive-cytoreductive-surgery-and-selective-neoadjuvant-chemotherapy-according-to-institutional-criteria-in-bulky-stage-iiic-and-iv-epithelial-ovarian-cancer
#14
Myong Cheol Lim, Heong Jong Yoo, Yong Jung Song, Sang Soo Seo, Sokbom Kang, Sun Ho Kim, Chong Woo Yoo, Sang Yoon Park
OBJECTIVE: To investigate the survival outcomes in patients with bulky stage IIIC and IV ovarian cancer, treated by primary debulking surgery (PDS) and selective use of neoadjuvant chemotherapy (NAC) according to institutional criteria. METHODS: Medical records for advanced ovarian cancer patients who were treated at National Cancer Center (NCC) between December 2000 and March 2009 were retrospectively reviewed in the comprehensive cancer center. Bulky stage IIIC and IV ovarian cancer cases were included...
July 2017: Journal of Gynecologic Oncology
https://www.readbyqxmd.com/read/28541631/germline-and-somatic-mutations-in-homologous-recombination-genes-among-chinese-ovarian-cancer-patients-detected-using-next-generation-sequencing
#15
Qianying Zhao, Jiaxin Yang, Lei Li, Dongyan Cao, Mei Yu, Keng Shen
OBJECTIVE: To define genetic profiling of homologous recombination (HR) deficiency in Chinese ovarian cancer patients. METHODS: we have applied next-generation sequencing to detect deleterious mutations through all exons in 31 core HR genes. Paired whole blood and frozen tumor samples from 50 Chinese women diagnosed with epithelial ovarian carcinomas were tested to identify both germline and somatic variants. RESULTS: Deleterious germline HR-mutations were identified in 36% of the ovarian cancer patients...
July 2017: Journal of Gynecologic Oncology
https://www.readbyqxmd.com/read/28540830/progress-in-the-management-of-primary-and-recurrent-ovarian-carcinomatosis-with-peritonectomy-procedure-and-hipec-in-a-high-volume-center
#16
A Arjona-Sanchez, S Rufián-Peña
INTRODUCTION: The treatment of advanced primary or recurrent ephitelial ovarian cancer still remains an open and a critical question. The addition of HIPEC to cytoreductive surgery has showed improving overall survival rates. The aim of our study is to describe the progress in its management in our Unit and what we have learned after more than 350 HIPEC procedures. METHODS: From 1997 to 2016 we conducted a retrospective analysis from a prospective database. We described and analyzed 4 cut-points, 1997-2004, 2009, 2012 and 2016...
March 29, 2017: International Journal of Hyperthermia
https://www.readbyqxmd.com/read/28540827/complete-cytoreductive-surgery-plus-hipec-for-peritoneal-metastases-from-unusual-cancer-sites-of-origin-results-from-a-worldwide-analysis-issue-of-the-peritoneal-surface-oncology-group-international-psogi
#17
Diane Goéré, Guillaume Passot, Maximiliano Gelli, Edward A Levine, David L Bartlett, Paul H Sugarbaker, Olivier Glehen
AIM: The aim of this study was to assess the outcomes of patients operated on for peritoneal metastases from unusual cancer sites of origin, meaning apart from PM from colorectal, gastric and epithelial ovarian carcinomas, pseudomyxoma peritonei and mesothelioma. PATIENTS AND METHODS: A questionnaire concerning patients treated with CRS plus HIPEC for PM arising from unusual cancer sites of origin was sent to all centers that routinely performed HIPEC, through the Peritoneal Surface Oncology Group International and the RENAPE network...
March 8, 2017: International Journal of Hyperthermia
https://www.readbyqxmd.com/read/28540826/drugs-doses-and-durations-of-intraperitoneal-chemotherapy-standardizing-hipec-and-epic-for-colorectal-appendiceal-gastric-ovarian-peritoneal-surface-malignancies-and-peritoneal-mesothelioma
#18
Lieselotte Lemoine, Paul Sugarbaker, Kurt Van der Speeten
Peritoneal surface malignancy (PSM) is a common manifestation of digestive and gynecologic malignancies alike. At present, patients with isolated PSM are treated with a combination therapy of cytoreductive surgery (CRS) and hyperthermic peroperative intraperitoneal chemotherapy (HIPEC). The combination of CRS and intraperitoneal (IP) chemotherapy should now be considered standard of care for PSM from appendiceal epithelial cancers, colorectal cancer and peritoneal mesothelioma. Although there is a near universal standardization regarding the CRS, we are still lacking a much-needed standardization amongst the various IP chemotherapy treatment modalities used today in clinical practice...
February 8, 2017: International Journal of Hyperthermia
https://www.readbyqxmd.com/read/28540777/acute-kidney-injury-in-ovarian-cancer-patients-undergoing-cytoreductive-surgery-and-hyperthermic-intra-peritoneal-chemotherapy
#19
Eliza I-Lin Sin, Claramae Shulyn Chia, Grace Hwei Ching Tan, Khee Chee Soo, Melissa Ching-Ching Teo
BACKGROUND: Cytoreductive surgery and hyperthermic intra-peritoneal chemotherapy (CRS-HIPEC) prolongs survival in patients with metastatic peritoneal disease. We look at the incidence of acute kidney injury (AKI) in patients who have received cisplatin during CRS-HIPEC in the treatment of peritoneal carcinomatosis from an ovarian primary, and identify possible peri-operative risk factors. METHODS: Between 2005 and 2013, we performed CRS-HIPEC on 47 patients with ovarian primaries and peritoneal metastasis...
March 5, 2017: International Journal of Hyperthermia
https://www.readbyqxmd.com/read/28527673/minimal-access-surgery-compared-to-laparotomy-for-secondary-surgical-cytoreduction-in-patients-with-recurrent-ovarian-carcinoma-perioperative-and-oncologic-outcomes
#20
Ane Gerda Z Eriksson, Ashley Graul, Miao C Yu, Anthony Halko, Dennis S Chi, Oliver Zivanovic, Ginger J Gardner, Yukio Sonoda, Richard R Barakat, Nadeem R Abu-Rustum, Mario M Leitao
OBJECTIVES: To assess the perioperative outcomes of minimal access surgery (MAS) in secondary surgical cytoreduction (SSCR) for recurrent epithelial ovarian cancer (ROC); to compare oncologic outcomes with laparotomy (LAP). METHODS: Using an institutional database, we identified all patients with ROC undergoing SSCR from 1/5/09-6/14/14. Selection for MAS or LAP was based on surgeon preference. To minimize selection bias, preoperative imaging was reviewed for all LAP cases...
May 17, 2017: Gynecologic Oncology
keyword
keyword
111476
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"